<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01913301</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-711-0530</org_study_id>
    <nct_id>NCT01913301</nct_id>
  </id_info>
  <brief_title>A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure</brief_title>
  <acronym>BREAK-DHF-1</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Clinical Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Clinical Studies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to gather information regarding the safety and effectiveness of&#xD;
      an investigational drug called Alagebrium when used treating Heart Failure in relation to&#xD;
      exercise tolerance after 6 months in the trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor lost funding&#xD;
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise Tolerance</measure>
    <time_frame>Change from baseline at Week 24</time_frame>
    <description>To evaluate the safety and efficacy of alagebrium in subjects diagnosed with diastolic heart failure. The primary variable for assessing efficacy will be assessment of exercise tolerance using the Six-minute walk test.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Alagebrium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alagebrium</intervention_name>
    <arm_group_label>Alagebrium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 50 years of age or older.&#xD;
&#xD;
          2. Diagnosis of diabetes OR a diagnosis of hypertension requiring therapy.&#xD;
&#xD;
          3. Echocardiographic ejection fraction ≥ 45% verified within 1 year prior to baseline,&#xD;
             assuming no intercurrent cardiac event between the echo and screening.&#xD;
&#xD;
          4. Echocardiographic evidence of diastolic dysfunction as defined by an E/E' ≥ 12&#xD;
             determined within 1 year prior to baseline; sinus rhythm required at time of echo.&#xD;
&#xD;
          5. Previous hospitalization due to heart failure OR a current or previous BNP ≥ 100&#xD;
             pg/mL.&#xD;
&#xD;
          6. New York Heart Association (NYHA) functional class II-IV.&#xD;
&#xD;
          7. At least 1 month between hospitalization for heart failure and randomization.&#xD;
&#xD;
          8. Stable doses of heart failure medications (diuretics, ACE inhibitors, ARB's,&#xD;
             beta-adrenergic antagonists, aldosterone antagonists) for at least 1 month prior to&#xD;
             randomization.&#xD;
&#xD;
          9. Able to understand content of and willing to provide written informed consent.&#xD;
&#xD;
         10. Agree to use adequate contraception during the study if premenopausal. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ejection fraction &lt; 45%.&#xD;
&#xD;
          2. Screening Six-minute walk test &gt; 450 meters or &lt; 100 meters&#xD;
&#xD;
          3. Clinically significant cardiac valvular disease (mitral regurgitation (MR) &gt; grade I,&#xD;
             aortic insufficiency (AI) &gt; grade 1, mitral stenosis (MS), aortic stenosis (AS)).&#xD;
&#xD;
          4. History of stroke, any sequelae of a transient ischemic attack (TIA), or reversible&#xD;
             ischemic neurological defect (RIND) within 6 months prior to screening.&#xD;
&#xD;
          5. History of acute myocardial infarction within 6 months prior to screening.&#xD;
&#xD;
          6. Severe COPD as defined by O2 or steroid dependence.&#xD;
&#xD;
          7. History of systemic inflammatory or collagen vascular disease.&#xD;
&#xD;
          8. Active and or treated malignancies within 12 months prior to Visit 1 with the&#xD;
             exception of basal cell carcinoma.&#xD;
&#xD;
          9. Any significant systemic illness(es) or medical condition(s) that could lead to&#xD;
             difficulty complying with the protocol; or any concurrent condition(s) which, in the&#xD;
             investigator's opinion, would prohibit the subject from completing the study, or would&#xD;
             not be in the best interest of the subject.&#xD;
&#xD;
         10. Estimated glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m² as calculated by&#xD;
             Modification of Diet in Renal Disease (MDRD) study equation [MDRD = 186 X serum&#xD;
             creatinine (mg/dl) 1.154 X years -0.203 X (0.742 if female) X (1.210 if African&#xD;
             American)].&#xD;
&#xD;
         11. Liver function tests (SGOT and/or SGPT) &gt; 2.5 times the upper limit of normal range.&#xD;
&#xD;
         12. Hb &lt; 10 g/dL.&#xD;
&#xD;
         13. Use of any investigational drug(s) within 30 days prior to screening.&#xD;
&#xD;
         14. Previous exposure to alagebrium.&#xD;
&#xD;
         15. Known seropositivity for HIV or hepatitis C, or presence of hepatitis B surface&#xD;
             antigen.&#xD;
&#xD;
         16. Pregnancy or active breast-feeding. Urine pregnancy tests will be performed on all&#xD;
             women who are not post-menopausal for at least 1 year.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2013</study_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 30, 2017</submitted>
    <returned>March 17, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

